Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| INOVIO PHARMACEUTICALS, INC.INO · Entity 6589 | CFO | May 20, 2026 | May 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
INOVIO PHARMACEUTICALS, INC.
Report date May 20, 2026 · Filed May 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 42,854 |
Ending reported balance
After 2026-05-20 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-05-20 · Exercise / conversion · Acquired 8,700 · Balance 47,542 F1: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 26,100 restricted stock units was as follows: 8,700 shares vested on May 20, 2026; 8,700 shares will vest on May 20, 2027; 8,700 shares will vest on May 20, 2028. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Row 2 · 2026-05-20 · Tax withholding · Disposed 4,688 · Balance 42,854 F2: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in the immediately preceding row and described in footnote (1) herein. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 17,400 |
Reported balance
After 2026-05-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-05-20 · Exercise / conversion · Disposed 8,700 · Balance 17,400 F1: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 26,100 restricted stock units was as follows: 8,700 shares vested on May 20, 2026; 8,700 shares will vest on May 20, 2027; 8,700 shares will vest on May 20, 2028. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 32,480 |
Reported balance
After 2026-05-20 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-05-20 · Grant · Acquired 32,480 · Balance 32,480 F5: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the restricted stock units granted on May 20, 2026 was as follows: 10,827 shares will vest on February 26, 2027; 10,827 shares will vest on February 26, 2028; and 10,826 shares will vest on February 26, 2029. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F6: The restricted stock units were approved by Inovio's Board of Directors on March 4, 2026, subject to shareholder approval of the amendment and restatement of the Amended and Restated 2023 Omnibus Incentive Plan under which the restricted stock units were granted. Inovio's shareholders approved the amendment and restatement of the Amended and Restated 2023 Omnibus Incentive Plan on May 20, 2026. |
| Common Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.73 · Expires 2036-05-20 | Direct | 39,760 |
Reported balance
After 2026-05-20 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-05-20 · Grant · Acquired 39,760 · Balance 39,760 F3: The stock option grant was approved by Inovio's Board of Directors on March 4, 2026, subject to shareholder approval of the amendment and restatement of the Amended and Restated 2023 Omnibus Incentive Plan under which the stock options were granted. Inovio's shareholders approved the amendment and restatement of the Amended and Restated 2023 Omnibus Incentive Plan on May 20, 2026. F4: The vesting schedule for the options granted on May 20, 2026 was as follows: 13,254 shares will vest on February 26, 2027; 13,253 shares will vest on February 26, 2028; 13,253 shares will vest on February 26, 2029. |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 375 |
Reported balance
Holding disclosure · report date 2026-05-20 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 375 |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 26,100 restricted stock units was as follows: 8,700 shares vested on May 20, 2026; 8,700 shares will vest on May 20, 2027; 8,700 shares will vest on May 20, 2028. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.
F2: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in the immediately preceding row and described in footnote (1) herein.
F3: The stock option grant was approved by Inovio's Board of Directors on March 4, 2026, subject to shareholder approval of the amendment and restatement of the Amended and Restated 2023 Omnibus Incentive Plan under which the stock options were granted. Inovio's shareholders approved the amendment and restatement of the Amended and Restated 2023 Omnibus Incentive Plan on May 20, 2026.
F4: The vesting schedule for the options granted on May 20, 2026 was as follows: 13,254 shares will vest on February 26, 2027; 13,253 shares will vest on February 26, 2028; 13,253 shares will vest on February 26, 2029.
F5: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the restricted stock units granted on May 20, 2026 was as follows: 10,827 shares will vest on February 26, 2027; 10,827 shares will vest on February 26, 2028; and 10,826 shares will vest on February 26, 2029. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.
F6: The restricted stock units were approved by Inovio's Board of Directors on March 4, 2026, subject to shareholder approval of the amendment and restatement of the Amended and Restated 2023 Omnibus Incentive Plan under which the restricted stock units were granted. Inovio's shareholders approved the amendment and restatement of the Amended and Restated 2023 Omnibus Incentive Plan on May 20, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 26, 2023 Filed Feb 28, 2023 22:42 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 22,544 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-23-000005 · wf-form4_167762408938905.xml · nonDerivative · entry 1 KIES PETER · CIK 0001259780 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201,828 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. On February 26, 2021, the reporting person was granted 67,633 restricted stock units, vesting as follows: 22,545 shares vested on February 26, 2022; 22,544 shares vested on February 26, 2023; and 22,544 shares will vest on February 26, 2024. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 11, 2022 Filed Mar 14, 2022 20:29 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 59,737 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-22-000019 · wf-form4_164728968540484.xml · derivative · entry 4 KIES PETER · CIK 0001259780 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,737 Underlying: Common Stock · 59,737 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 179,211 restricted stock units is as follows: 59,737 shares vested on March 11, 2021; 59,737 shares vested on March 11, 2022; 59,737 shares will vest on March 11, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 179,211 restricted stock units is as follows: 59,737 shares vested on March 11, 2021; 59,737 shares vested on March 11, 2022; 59,737 shares will vest on March 11, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 179,211 restricted stock units is as follows: 59,737 shares vested on March 11, 2021; 59,737 shares vested on March 11, 2022; 59,737 shares will vest on March 11, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 179,211 restricted stock units is as follows: 59,737 shares vested on March 11, 2021; 59,737 shares vested on March 11, 2022; 59,737 shares will vest on March 11, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 11, 2022 Filed Mar 14, 2022 20:29 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Tax withholdingCommon Stock | 31,410 | $3.22 | $101,140.20 |
DisclosureSEC source: 0001055726-22-000019 · wf-form4_164728968540484.xml · nonDerivative · entry 2 KIES PETER · CIK 0001259780 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,284 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in footnote (1) herein. Read SEC document |
| March 11, 2022 Filed Mar 14, 2022 20:29 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 59,737 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-22-000019 · wf-form4_164728968540484.xml · nonDerivative · entry 1 KIES PETER · CIK 0001259780 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,694 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 179,211 restricted stock units is as follows: 59,737 shares vested on March 11, 2021; 59,737 shares vested on March 11, 2022; 59,737 shares will vest on March 11, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 08, 2022 Filed Mar 9, 2022 21:08 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 21,466 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-22-000017 · wf-form4_164686011126212.xml · derivative · entry 4 KIES PETER · CIK 0001259780 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,466 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 64,400 restricted stock units is as follows: 21,467 shares vested on March 8, 2020; 21,467 shares vested on March 8, 2021; 21,466 shares vested on March 8, 2022. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 64,400 restricted stock units is as follows: 21,467 shares vested on March 8, 2020; 21,467 shares vested on March 8, 2021; 21,466 shares vested on March 8, 2022. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 64,400 restricted stock units is as follows: 21,467 shares vested on March 8, 2020; 21,467 shares vested on March 8, 2021; 21,466 shares vested on March 8, 2022. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 64,400 restricted stock units is as follows: 21,467 shares vested on March 8, 2020; 21,467 shares vested on March 8, 2021; 21,466 shares vested on March 8, 2022. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 08, 2022 Filed Mar 9, 2022 21:08 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Tax withholdingCommon Stock | 11,287 | $3.26 | $36,795.62 |
DisclosureSEC source: 0001055726-22-000017 · wf-form4_164686011126212.xml · nonDerivative · entry 2 KIES PETER · CIK 0001259780 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,957 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in footnote (1) herein. Read SEC document |
| March 08, 2022 Filed Mar 9, 2022 21:08 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 21,466 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-22-000017 · wf-form4_164686011126212.xml · nonDerivative · entry 1 KIES PETER · CIK 0001259780 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,244 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 64,400 restricted stock units is as follows: 21,467 shares vested on March 8, 2020; 21,467 shares vested on March 8, 2021; 21,466 shares vested on March 8, 2022. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| February 26, 2022 Filed Mar 1, 2022 23:49 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantRestricted Stock Unit · Derivative | 143,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-22-000012 · wf-form4_164617858308647.xml · derivative · entry 6 KIES PETER · CIK 0001259780 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,900 Underlying: Common Stock · 143,900 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 143,900 restricted stock units is as follows: 47,967 shares will vest on February 26, 2023; 47,967 shares will vest on February 26, 2024; 47,966 shares will vest on February 26, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F4 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 143,900 restricted stock units is as follows: 47,967 shares will vest on February 26, 2023; 47,967 shares will vest on February 26, 2024; 47,966 shares will vest on February 26, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F4 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 143,900 restricted stock units is as follows: 47,967 shares will vest on February 26, 2023; 47,967 shares will vest on February 26, 2024; 47,966 shares will vest on February 26, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F4 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 143,900 restricted stock units is as follows: 47,967 shares will vest on February 26, 2023; 47,967 shares will vest on February 26, 2024; 47,966 shares will vest on February 26, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| February 26, 2022 Filed Mar 1, 2022 23:49 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantCommon Stock Option · Derivative | 192,800 | $0.00 Strike: $3.22 | $0.00 |
DisclosureSEC source: 0001055726-22-000012 · wf-form4_164617858308647.xml · derivative · entry 5 KIES PETER · CIK 0001259780 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,800 Underlying: Common Stock · 192,800 shares Expires 2032-02-26 F3 · derivative.exercise_date: The vesting schedule for the 192,800 options is as follows: 48,200 shares vested on February 26, 2022; 48,200 shares will vest on February 26, 2023; 48,200 shares will vest on February 26, 2024; 48,200 shares will vest on February 26, 2025. Read SEC document |
| February 26, 2022 Filed Mar 1, 2022 23:49 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 22,545 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-22-000012 · wf-form4_164617858308647.xml · derivative · entry 4 KIES PETER · CIK 0001259780 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,088 Underlying: Common Stock · 22,545 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 67,633 restricted stock units is as follows: 22,545 shares vested on February 26, 2022; 22,544 shares will vest on February 26, 2023; 22,544 shares will vest on February 26, 2024. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 67,633 restricted stock units is as follows: 22,545 shares vested on February 26, 2022; 22,544 shares will vest on February 26, 2023; 22,544 shares will vest on February 26, 2024. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 67,633 restricted stock units is as follows: 22,545 shares vested on February 26, 2022; 22,544 shares will vest on February 26, 2023; 22,544 shares will vest on February 26, 2024. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 67,633 restricted stock units is as follows: 22,545 shares vested on February 26, 2022; 22,544 shares will vest on February 26, 2023; 22,544 shares will vest on February 26, 2024. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| February 26, 2022 Filed Mar 1, 2022 23:49 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Tax withholdingCommon Stock | 12,555 | $3.22 | $40,427.10 |
DisclosureSEC source: 0001055726-22-000012 · wf-form4_164617858308647.xml · nonDerivative · entry 2 KIES PETER · CIK 0001259780 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,778 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in footnote (1) herein. Read SEC document |
| February 26, 2022 Filed Mar 1, 2022 23:49 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 22,545 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-22-000012 · wf-form4_164617858308647.xml · nonDerivative · entry 1 KIES PETER · CIK 0001259780 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 67,633 restricted stock units is as follows: 22,545 shares vested on February 26, 2022; 22,544 shares will vest on February 26, 2023; 22,544 shares will vest on February 26, 2024. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| June 09, 2021 Filed Jun 11, 2021 20:24 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock Option · Derivative | 13,750 | $0.00 Strike: $2.16 | $0.00 |
DisclosureSEC source: 0001055726-21-000050 · wf-form4_162344304755381.xml · derivative · entry 4 KIES PETER · CIK 0001259780 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 13,750 shares Expires 2023-03-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 09, 2021 Filed Jun 11, 2021 20:24 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | SaleCommon Stock | 33,750 | $10.01 | $337,837.50 |
DisclosureSEC source: 0001055726-21-000050 · wf-form4_162344304755381.xml · nonDerivative · entry 2 KIES PETER · CIK 0001259780 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,788 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: These transactions were executed in multiple trades at prices ranging from $10.00 to $10.04, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| June 09, 2021 Filed Jun 11, 2021 20:24 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 13,750 | $2.16 | $29,700.00 |
DisclosureSEC source: 0001055726-21-000050 · wf-form4_162344304755381.xml · nonDerivative · entry 1 KIES PETER · CIK 0001259780 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,538 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 03, 2021 Filed Jun 4, 2021 20:08 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | SaleCommon Stock | 10,000 | $8.03 | $80,300.00 |
DisclosureSEC source: 0001055726-21-000049 · wf-form4_162283729943316.xml · nonDerivative · entry 1 KIES PETER · CIK 0001259780 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,788 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: These transactions were executed in multiple trades at prices ranging from $8.00 to $8.09, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| April 21, 2021 Filed Apr 21, 2021 22:00 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | SaleCommon Stock | 10,000 | $8.52 | $85,200.00 |
DisclosureSEC source: 0001055726-21-000037 · wf-form4_161904242442411.xml · nonDerivative · entry 1 KIES PETER · CIK 0001259780 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,788 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: These transactions were executed in multiple trades at prices ranging from $8.49 to $8.56, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| March 11, 2021 Filed Mar 12, 2021 23:36 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 59,737 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-21-000027 · wf-form4_161559215079850.xml · derivative · entry 4 KIES PETER · CIK 0001259780 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,474 Underlying: Common Stock · 59,737 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 179,211 restricted stock units is as follows: 59,737 shares vested on March 11, 2021; 59,737 shares will vest on March 11, 2022; 59,737 shares will vest on March 11, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 179,211 restricted stock units is as follows: 59,737 shares vested on March 11, 2021; 59,737 shares will vest on March 11, 2022; 59,737 shares will vest on March 11, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 179,211 restricted stock units is as follows: 59,737 shares vested on March 11, 2021; 59,737 shares will vest on March 11, 2022; 59,737 shares will vest on March 11, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 179,211 restricted stock units is as follows: 59,737 shares vested on March 11, 2021; 59,737 shares will vest on March 11, 2022; 59,737 shares will vest on March 11, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 11, 2021 Filed Mar 12, 2021 23:36 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Tax withholdingCommon Stock | 31,410 | $10.57 | $332,003.70 |
DisclosureSEC source: 0001055726-21-000027 · wf-form4_161559215079850.xml · nonDerivative · entry 2 KIES PETER · CIK 0001259780 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,788 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in footnote (1) herein. Read SEC document |
| March 11, 2021 Filed Mar 12, 2021 23:36 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 59,737 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-21-000027 · wf-form4_161559215079850.xml · nonDerivative · entry 1 KIES PETER · CIK 0001259780 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,198 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 179,211 restricted stock units is as follows: 59,737 shares vested on March 11, 2021; 59,737 shares will vest on March 11, 2022; 59,737 shares will vest on March 11, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 08, 2021 Filed Mar 10, 2021 00:02 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 21,467 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-21-000019 · wf-form4_161533452463255.xml · derivative · entry 7 KIES PETER · CIK 0001259780 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,466 Underlying: Common Stock · 21,467 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 64,400 restricted stock units is as follows: 21,467 shares vested on March 8, 2020; 21,467 shares vested on March 8, 2021; 21,466 shares will vest on March 8, 2022.Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F3 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 64,400 restricted stock units is as follows: 21,467 shares vested on March 8, 2020; 21,467 shares vested on March 8, 2021; 21,466 shares will vest on March 8, 2022.Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 64,400 restricted stock units is as follows: 21,467 shares vested on March 8, 2020; 21,467 shares vested on March 8, 2021; 21,466 shares will vest on March 8, 2022.Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 64,400 restricted stock units is as follows: 21,467 shares vested on March 8, 2020; 21,467 shares vested on March 8, 2021; 21,466 shares will vest on March 8, 2022.Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 08, 2021 Filed Mar 10, 2021 00:02 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Tax withholdingCommon Stock | 11,288 | $8.91 | $100,576.08 |
DisclosureSEC source: 0001055726-21-000019 · wf-form4_161533452463255.xml · nonDerivative · entry 4 KIES PETER · CIK 0001259780 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,461 F4 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in footnote (3) herein. Read SEC document |
| March 08, 2021 Filed Mar 10, 2021 00:02 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 21,467 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-21-000019 · wf-form4_161533452463255.xml · nonDerivative · entry 3 KIES PETER · CIK 0001259780 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,749 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 64,400 restricted stock units is as follows: 21,467 shares vested on March 8, 2020; 21,467 shares vested on March 8, 2021; 21,466 shares will vest on March 8, 2022.Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 05, 2021 Filed Mar 10, 2021 00:02 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 27,566 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-21-000019 · wf-form4_161533452463255.xml · derivative · entry 6 KIES PETER · CIK 0001259780 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,566 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 82,700 restricted stock units is as follows: 27,567 shares vested on March 5, 2019; 27,567 shares vested on March 5, 2020; 27,566 shares vested on March 5, 2021. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 82,700 restricted stock units is as follows: 27,567 shares vested on March 5, 2019; 27,567 shares vested on March 5, 2020; 27,566 shares vested on March 5, 2021. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 82,700 restricted stock units is as follows: 27,567 shares vested on March 5, 2019; 27,567 shares vested on March 5, 2020; 27,566 shares vested on March 5, 2021. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 82,700 restricted stock units is as follows: 27,567 shares vested on March 5, 2019; 27,567 shares vested on March 5, 2020; 27,566 shares vested on March 5, 2021. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 05, 2021 Filed Mar 10, 2021 00:02 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Tax withholdingCommon Stock | 14,574 | $9.19 | $133,935.06 |
DisclosureSEC source: 0001055726-21-000019 · wf-form4_161533452463255.xml · nonDerivative · entry 2 KIES PETER · CIK 0001259780 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,282 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in footnote (1) herein. Read SEC document |
| March 05, 2021 Filed Mar 10, 2021 00:02 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 27,566 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-21-000019 · wf-form4_161533452463255.xml · nonDerivative · entry 1 KIES PETER · CIK 0001259780 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,856 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 82,700 restricted stock units is as follows: 27,567 shares vested on March 5, 2019; 27,567 shares vested on March 5, 2020; 27,566 shares vested on March 5, 2021. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| February 26, 2021 Filed Feb 27, 2021 00:09 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantRestricted Stock Unit · Derivative | 67,633 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-21-000014 · wf-form4_161438452513748.xml · derivative · entry 2 KIES PETER · CIK 0001259780 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,633 Underlying: Common Stock · 67,633 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 67,633 restricted stock units is as follows: 22,544 shares will vest on February 26, 2022; 22,544 shares will vest on February 26, 2023; 22,545 shares will vest on February 26, 2024. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F2 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 67,633 restricted stock units is as follows: 22,544 shares will vest on February 26, 2022; 22,544 shares will vest on February 26, 2023; 22,545 shares will vest on February 26, 2024. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 67,633 restricted stock units is as follows: 22,544 shares will vest on February 26, 2022; 22,544 shares will vest on February 26, 2023; 22,545 shares will vest on February 26, 2024. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| February 26, 2021 Filed Feb 27, 2021 00:09 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantCommon Stock Option · Derivative | 104,833 | $0.00 Strike: $11.10 | $0.00 |
DisclosureSEC source: 0001055726-21-000014 · wf-form4_161438452513748.xml · derivative · entry 1 KIES PETER · CIK 0001259780 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,833 Underlying: Common Stock · 104,833 shares Expires 2031-02-26 F1 · derivative.exercise_date: The vesting schedule for the 104,833 options is as follows: 26,208 shares vested on February 26, 2021; 26,208 shares will vest on February 26, 2022; 26,208 shares will vest on February 26, 2023; 26,209 shares will vest on February 26, 2024. Read SEC document |
| January 15, 2021 Filed Jan 16, 2021 00:25 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock Option · Derivative | 30,000 | $0.00 Strike: $4.56 | $0.00 |
DisclosureSEC source: 0001055726-21-000004 · wf-form4_161075672601972.xml · derivative · entry 4 KIES PETER · CIK 0001259780 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2021-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Gives effect to a 1-for-4 reverse stock split effected by the Issuer on June 5, 2014. F3 · shares: Gives effect to a 1-for-4 reverse stock split effected by the Issuer on June 5, 2014. F3 · derivative.underlying_shares: Gives effect to a 1-for-4 reverse stock split effected by the Issuer on June 5, 2014. Read SEC document |
| January 15, 2021 Filed Jan 16, 2021 00:25 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | SaleCommon Stock | 30,000 | $10.02 | $300,558.00 |
DisclosureSEC source: 0001055726-21-000004 · wf-form4_161075672601972.xml · nonDerivative · entry 2 KIES PETER · CIK 0001259780 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,290 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: These transactions were executed in multiple trades at prices ranging from $10.00 to $10.07, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| January 15, 2021 Filed Jan 16, 2021 00:25 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 30,000 | $4.56 | $136,800.00 |
DisclosureSEC source: 0001055726-21-000004 · wf-form4_161075672601972.xml · nonDerivative · entry 1 KIES PETER · CIK 0001259780 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,290 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 15, 2020 Filed Dec 18, 2020 00:07 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock Option · Derivative | 11,250 | $0.00 Strike: $2.16 | $0.00 |
DisclosureSEC source: 0001055726-20-000056 · wf-form4_160825002177388.xml · derivative · entry 6 KIES PETER · CIK 0001259780 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,750 Underlying: Common Stock · 11,250 shares Expires 2023-03-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Gives effect to a 1-for-4 reverse stock split effected by the Issuer on June 5, 2014. F3 · shares: Gives effect to a 1-for-4 reverse stock split effected by the Issuer on June 5, 2014. F3 · derivative.underlying_shares: Gives effect to a 1-for-4 reverse stock split effected by the Issuer on June 5, 2014. Read SEC document |
| December 15, 2020 Filed Dec 18, 2020 00:07 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock Option · Derivative | 8,750 | $0.00 Strike: $2.40 | $0.00 |
DisclosureSEC source: 0001055726-20-000056 · wf-form4_160825002177388.xml · derivative · entry 5 KIES PETER · CIK 0001259780 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,750 shares Expires 2022-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Gives effect to a 1-for-4 reverse stock split effected by the Issuer on June 5, 2014. F3 · shares: Gives effect to a 1-for-4 reverse stock split effected by the Issuer on June 5, 2014. F3 · derivative.underlying_shares: Gives effect to a 1-for-4 reverse stock split effected by the Issuer on June 5, 2014. Read SEC document |
| December 15, 2020 Filed Dec 18, 2020 00:07 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | SaleCommon Stock | 20,000 | $10.69 | $213,706.00 |
DisclosureSEC source: 0001055726-20-000056 · wf-form4_160825002177388.xml · nonDerivative · entry 3 KIES PETER · CIK 0001259780 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,290 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: These transactions were executed in multiple trades at prices ranging from $10.52 to $10.83, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| December 15, 2020 Filed Dec 18, 2020 00:07 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 11,250 | $2.16 | $24,300.00 |
DisclosureSEC source: 0001055726-20-000056 · wf-form4_160825002177388.xml · nonDerivative · entry 2 KIES PETER · CIK 0001259780 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,290 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 15, 2020 Filed Dec 18, 2020 00:07 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 8,750 | $2.40 | $21,000.00 |
DisclosureSEC source: 0001055726-20-000056 · wf-form4_160825002177388.xml · nonDerivative · entry 1 KIES PETER · CIK 0001259780 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,040 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 15, 2020 Filed Jul 17, 2020 23:00 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock Option · Derivative | 35,000 | $0.00 Strike: $2.40 | $0.00 |
DisclosureSEC source: 0001055726-20-000044 · wf-form4_159502681136667.xml · derivative · entry 4 KIES PETER · CIK 0001259780 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,000 shares Expires 2022-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Gives effect to a 1-for-4 reverse stock split effected by the Issuer on June 5, 2014. F3 · shares: Gives effect to a 1-for-4 reverse stock split effected by the Issuer on June 5, 2014. F3 · derivative.underlying_shares: Gives effect to a 1-for-4 reverse stock split effected by the Issuer on June 5, 2014. Read SEC document |
| July 15, 2020 Filed Jul 17, 2020 23:00 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | SaleCommon Stock | 35,000 | $24.95 | $873,208.00 |
DisclosureSEC source: 0001055726-20-000044 · wf-form4_159502681136667.xml · nonDerivative · entry 2 KIES PETER · CIK 0001259780 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,290 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: These transactions were executed in multiple trades at prices ranging from $24.21 to $25.45, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| July 15, 2020 Filed Jul 17, 2020 23:00 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 35,000 | $2.40 | $84,000.00 |
DisclosureSEC source: 0001055726-20-000044 · wf-form4_159502681136667.xml · nonDerivative · entry 1 KIES PETER · CIK 0001259780 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,290 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 30, 2020 Filed Jul 3, 2020 01:05 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | SaleCommon Stock | 35,000 | $26.50 | $927,500.00 |
DisclosureSEC source: 0001055726-20-000043 · wf-form4_159373831691639.xml · nonDerivative · entry 1 KIES PETER · CIK 0001259780 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,290 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: These transactions were executed in multiple trades at prices ranging from $26.13 to $26.69, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| March 11, 2020 Filed Mar 12, 2020 20:41 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | GrantRestricted Stock Unit · Derivative | 179,211 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-20-000014 · wf-form4_158404568493227.xml · derivative · entry 5 KIES PETER · CIK 0001259780 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,211 Underlying: Common Stock · 179,211 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 179,211 restricted stock units is as follows: 59,737 shares will vest on March 11, 2021; 59,737 shares will vest on March 11, 2022; 59,737 shares will vest on March 11, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 179,211 restricted stock units is as follows: 59,737 shares will vest on March 11, 2021; 59,737 shares will vest on March 11, 2022; 59,737 shares will vest on March 11, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 179,211 restricted stock units is as follows: 59,737 shares will vest on March 11, 2021; 59,737 shares will vest on March 11, 2022; 59,737 shares will vest on March 11, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 10, 2020 Filed Mar 12, 2020 20:41 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 20,433 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-20-000014 · wf-form4_158404568493227.xml · derivative · entry 4 KIES PETER · CIK 0001259780 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,433 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 61,300 restricted stock units is as follows: 20,434 shares vested on March 10, 2018; 20,433 shares vested on March 10, 2019; 20,433 shares vested on March 10, 2020. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 61,300 restricted stock units is as follows: 20,434 shares vested on March 10, 2018; 20,433 shares vested on March 10, 2019; 20,433 shares vested on March 10, 2020. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 61,300 restricted stock units is as follows: 20,434 shares vested on March 10, 2018; 20,433 shares vested on March 10, 2019; 20,433 shares vested on March 10, 2020. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 61,300 restricted stock units is as follows: 20,434 shares vested on March 10, 2018; 20,433 shares vested on March 10, 2019; 20,433 shares vested on March 10, 2020. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 10, 2020 Filed Mar 12, 2020 20:41 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Tax withholdingCommon Stock | 7,066 | $5.70 | $40,276.20 |
DisclosureSEC source: 0001055726-20-000014 · wf-form4_158404568493227.xml · nonDerivative · entry 2 KIES PETER · CIK 0001259780 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,290 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in footnote (1) herein. Read SEC document |
| March 10, 2020 Filed Mar 12, 2020 20:41 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 20,433 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-20-000014 · wf-form4_158404568493227.xml · nonDerivative · entry 1 KIES PETER · CIK 0001259780 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,356 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 61,300 restricted stock units is as follows: 20,434 shares vested on March 10, 2018; 20,433 shares vested on March 10, 2019; 20,433 shares vested on March 10, 2020. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 08, 2020 Filed Mar 9, 2020 20:15 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 21,467 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-20-000006 · wf-form4_158378489893679.xml · derivative · entry 7 KIES PETER · CIK 0001259780 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,933 Underlying: Common Stock · 21,467 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 64,400 restricted stock units is as follows: 21,467 shares vested on March 8, 2020; 21,467 shares will vest on March 8, 2021; 21,466 shares will vest on March 8, 2022.Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F3 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 64,400 restricted stock units is as follows: 21,467 shares vested on March 8, 2020; 21,467 shares will vest on March 8, 2021; 21,466 shares will vest on March 8, 2022.Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 64,400 restricted stock units is as follows: 21,467 shares vested on March 8, 2020; 21,467 shares will vest on March 8, 2021; 21,466 shares will vest on March 8, 2022.Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 64,400 restricted stock units is as follows: 21,467 shares vested on March 8, 2020; 21,467 shares will vest on March 8, 2021; 21,466 shares will vest on March 8, 2022.Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 08, 2020 Filed Mar 9, 2020 20:15 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Tax withholdingCommon Stock | 7,424 | $14.09 | $104,604.16 |
DisclosureSEC source: 0001055726-20-000006 · wf-form4_158378489893679.xml · nonDerivative · entry 4 KIES PETER · CIK 0001259780 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,923 F4 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in footnote (3) herein. Read SEC document |
| March 08, 2020 Filed Mar 9, 2020 20:15 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 21,467 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-20-000006 · wf-form4_158378489893679.xml · nonDerivative · entry 3 KIES PETER · CIK 0001259780 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,347 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 64,400 restricted stock units is as follows: 21,467 shares vested on March 8, 2020; 21,467 shares will vest on March 8, 2021; 21,466 shares will vest on March 8, 2022.Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 05, 2020 Filed Mar 9, 2020 20:15 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionRestricted Stock Unit · Derivative | 27,567 | $0.00 | $0.00 |
DisclosureSEC source: 0001055726-20-000006 · wf-form4_158378489893679.xml · derivative · entry 6 KIES PETER · CIK 0001259780 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,566 Underlying: Common Stock · 27,567 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 82,700 restricted stock units is as follows: 27,567 shares vested on March 5, 2019; 27,567 shares vested on March 5, 2020; 27,566 shares will vest on March 5, 2021. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 82,700 restricted stock units is as follows: 27,567 shares vested on March 5, 2019; 27,567 shares vested on March 5, 2020; 27,566 shares will vest on March 5, 2021. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 82,700 restricted stock units is as follows: 27,567 shares vested on March 5, 2019; 27,567 shares vested on March 5, 2020; 27,566 shares will vest on March 5, 2021. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 82,700 restricted stock units is as follows: 27,567 shares vested on March 5, 2019; 27,567 shares vested on March 5, 2020; 27,566 shares will vest on March 5, 2021. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
| March 05, 2020 Filed Mar 9, 2020 20:15 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Tax withholdingCommon Stock | 9,817 | $9.80 | $96,206.60 |
DisclosureSEC source: 0001055726-20-000006 · wf-form4_158378489893679.xml · nonDerivative · entry 2 KIES PETER · CIK 0001259780 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,880 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in footnote (1) herein. Read SEC document |
| March 05, 2020 Filed Mar 9, 2020 20:15 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 27,567 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-20-000006 · wf-form4_158378489893679.xml · nonDerivative · entry 1 KIES PETER · CIK 0001259780 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,697 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 82,700 restricted stock units is as follows: 27,567 shares vested on March 5, 2019; 27,567 shares vested on March 5, 2020; 27,566 shares will vest on March 5, 2021. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.